or Try an Advanced Search...

    Enzyme Replacement Therapy Stocks List

    Symbol Grade Name % Change
    BMRN B BioMarin Pharmaceutical Inc. -1.60
    RARE D Ultragenyx Pharmaceutical Inc. -2.33
    FOLD D Amicus Therapeutics, Inc. 2.71
    PLX F Protalix BioTherapeutics, Inc. 1.77
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Rare Diseases Biotechnology Fabry Disease Gaucher Disease Inborn Errors Of Metabolism Life Sciences Lysosomal Storage Disorder Medicine Mucopolysaccharidosis Pompe Disease Achondroplasia Acid Autoimmune Disease Autoimmune Disorders Biodefense Biologics Biology Cancer Choline

    Related ETFs - A few ETFs which own one or more of the above listed Enzyme Replacement Therapy stocks.

    Symbol Grade Name Weight
    GNOM D Global X Genomics & Biotechnology ETF 8.86
    PBE D PowerShares Dynamic Biotech & Genome 7.68
    BBP D BioShares Biotechnology Products Fund 5.62
    LABD B Direxion Daily S&P Biotech Bear 3X Shares 4.76
    TMFM B Motley Fool Mid-Cap Growth ETF 4.15
    View all Enzyme Replacement Therapy ETFs...
    Compare ETFs
    Compare GNOM to BBP Compare PBE to BBP Compare PBE to TMFM

        Enzyme Replacement Therapy Stocks Recent News

        Date Stock Title
        Apr 19 FOLD When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?
        Apr 18 BMRN Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
        Apr 17 BMRN BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
        Apr 16 RARE As more rare disease therapies launch, their prices are rising
        Apr 16 RARE Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
        Apr 15 RARE Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
        Apr 15 RARE Ultragenyx reports serious adverse effects in gene therapy trial
        Apr 15 RARE Ultragenyx says Angelman therapy is working, but safety questions remain
        Apr 15 RARE Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
        Apr 12 BMRN Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Rare Diseases Biotechnology Fabry Disease Gaucher Disease Inborn Errors Of Metabolism Life Sciences Lysosomal Storage Disorder Medicine Mucopolysaccharidosis Pompe Disease Achondroplasia Acid Autoimmune Disease Autoimmune Disorders Biodefense Biologics Biology Cancer Choline
        Enzyme Replacement Therapy

        Enzyme replacement therapy (ERT) is a type of medical treatment used to replace enzymes that are missing or not working properly in the body. It is used to treat a variety of genetic disorders, including lysosomal storage diseases, such as Gaucher disease, Fabry disease, and Pompe disease. ERT involves the intravenous administration of a recombinant enzyme, which is a laboratory-made version of the enzyme that is missing or not working properly in the body. The enzyme helps to break down substances that would otherwise accumulate in the body, leading to symptoms and complications.

        Browse All Tags